|
Summary of Significant Accounting Policies (Details Textual) (USD $)
|
12 Months Ended | 101 Months Ended | ||
|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
|
Sep. 21, 2012
|
|
| Summary Of Significant Accounting Policies [Line Items] | ||||
| Research and Development Expense | $ 879,886 | $ 1,012,144 | $ 5,449,678 | |
| Deferred Setup and Organization Costs, Amortization Period (in months) | 180 months | |||
| Deferred Setup and Organization Costs, Amortization Period (in Years) | 20 years | |||
| Clinical Research And Development Cost Percentage | 32.00% | 16.00% | ||
| Fees For Services Total | 14,964 | 163,661 | ||
|
Agreement With Theradex Systems [Member]
|
||||
| Summary Of Significant Accounting Policies [Line Items] | ||||
| Annual Fee Payable, Clinical Trial | 2,000,000 | |||
| Clinical Cost Charged To Operations Total | 278,721 | |||
| Clinical Research And Development Cost Percentage | 2.00% | |||
| Fees For Services Total | 14,964 | 163,661 | 194,551 | |
|
Patents [Member]
|
||||
| Summary Of Significant Accounting Policies [Line Items] | ||||
| Research and Development Expense | $ 405,285 | $ 236,784 | $ 1,814,682 | |